Abstract: A spiky metal organic framework is provided in the present disclosure. The spiky metal organic framework is formed by a coordination reaction between at least one metal ion and an organic ligand, and includes a body and a plurality of spike-like structures. The body is a spherical shape, and a particle size of the body is 1 ?m to 3 ?m. The spike-like structures are distributed on a surface of the body, a diameter of each spike-like structure is 15 nm to 35 nm, and a length of each spike-like structure is 250 nm to 400 nm.

Abstract: A method for fabricating an oral drug delivery system includes steps as follows. A mixture is provided, which includes an organic ligand, a metal ion, a biological macromolecule and water. A coating step is performed for forming a biomimetic mineralized carrier encapsulated the biological macromolecule having a surface with the positive charge. A first solution including the biomimetic mineralized carrier is provided. A second solution including a yeast capsule is provided, wherein the yeast capsule has a surface with the negative charge. A loading step is performing, wherein the first solution is mixed with the second solution and then shaken for a shaking time, and the biomimetic mineralized carrier is loaded into the yeast capsule by an electrostatic force to form the oral drug delivery system.

Abstract: The present disclosure provides an oral drug composition including a prodrug and a carrier. The prodrug bonds an active drug to a spacer with a covalent bond, in which the spacer has a disulfide bond. The carrier is for carrying the prodrug with an efficient amount, and the carrier includes a ?-1,3-D-glucan.

Abstract: A spiky metal organic framework is provided in the present disclosure. The spiky metal organic framework is formed by a coordination reaction between at least one metal ion and an organic ligand, and includes a body and a plurality of spike-like structures. The body is a spherical shape, and a particle size of the body is 1 ?m to 3 ?m. The spike-like structures are distributed on a surface of the body, a diameter of each spike-like structure is 15 nm to 35 nm, and a length of each spike-like structure is 250 nm to 400 nm.

Abstract: The present disclosure provides an oral drug composition including a prodrug and a carrier. The prodrug bonds an active drug to a spacer with a covalent bond, in which the spacer has a disulfide bond. The carrier is for carrying the prodrug with an efficient amount, and the carrier includes a ?-1,3-D-glucan.

Abstract: An oral drug delivery system includes a biomimetic mineralized carrier and a yeast capsule. The biomimetic mineralized carrier has a surface with positive charge and includes a metal organic framework having an internal space and a biological macromolecule encapsulated in the internal space of the metal organic framework. A surface of the metal organic framework has a plurality of pores. The yeast capsule is composed of a ?-glucan cell-wall shell that removes a cytoplasm from yeast and has a surface with negative charge. The biomimetic mineralized carrier is loaded into the yeast capsule by an electrostatic force to form the oral drug delivery system.

Abstract: A method of preparing a lipid nanocarrier for encapsulating a hydrophilic protein is provided. The preparing method includes the following steps. The hydrophilic protein, a lipophilic component, and a wetting agent are mixed to obtain a homogeneous solution. The homogeneous solution and a saturated salt solution comprising a surfactant are mixed to obtain the lipid nanocarrier in a single-step emulsification manner.

Abstract: An immunothermosensitive composition is provided in the present disclosure. The immunothermosensitive composition includes a carrier and an immune adjuvant. The shell is carrier formed by self-assembly of a hydrophilic amine-containing polymer and a conductive polymer to form a hydrophilic region and a hydrophobic region, and the hydrophilic region is located outside the hydrophobic region. The immune adjuvant is coated in the hydrophobic region of the carrier, wherein the immune adjuvant specifically binds to Toll-Like Receptor 7 (TLR7) and/or Toll-Like Receptor 8 (TLR8). The immunothermosensitive composition can absorb light energy to generate thermal energy and is maintained at a temperature greater than or equal to 39° C. and less than or equal to 45° C.

Abstract: A pharmaceutical composition for oral delivery of hydrophobic small molecule drug and hydrophilic small molecule drug concurrently is provided. The pharmaceutical composition includes an enteric layer and a drug layer, in which the drug layer is encapsulated in the enteric layer. The drug layer includes a therapeutically effective amount of a hydrophobic small molecule drug, a therapeutically effective amount of a hydrophilic small molecule drug, a lipophilic solvent, an acidic compound and an effervescent ingredient.

Abstract: A sustained-release composition is provided in the present disclosure for producing a therapeutic gas, such as hydrogen. The sustained-release composition includes a precursor and a carrier. The precursor is magnesium, and the carrier is for carrying the precursor with an efficient amount, wherein the carrier includes a poly lactic-co-glycolic acid copolymer.

Abstract: The present disclosure provides a sustained-release composition including a sodium hydrosulfide and a carrier. The carrier is provided for carrying the sodium hydrosulfide with an effective amount and includes a first component and a second component. The first component includes a paraffin wax, and the second component includes a fatty alcohol, a fatty acid or a phospholipid. The present disclosure also provides a method for fabricating the sustained-release composition. The method includes providing a first solution, providing the carrier, providing a second solution, performing an oil-in-water emulsification, and cooling the emulsion. In addition, the present disclosure provides a method for treating the chronic wounds. The method includes administering an effective amount of the aforementioned sustained-release composition to a subject suffered from the chronic wounds.

Abstract: A sustained-release composition is provided in the present disclosure for producing a therapeutic gas, such as hydrogen sulfide or hydrogen. The sustained-release composition includes a precursor and a carrier. The precursor is diallyl trisulfide or magnesium, and the carrier includes a poly lactic-co-glycolic acid copolymer for carrying the precursor with an efficient amount.

Abstract: A pharmaceutical composition for oral delivery is provided with a poorly water-soluble drug; solvent with lipophilic tails and hydrophilic ends; an acid initiator; and a foaming agent generating carbon dioxide bubbles when the acid initiator is dissolved into the intestinal fluid to form an acidic environment. The poorly water-soluble drug is dissolved in the solvent to form a self-assembled monolayer carrier system with the bile salts surrounding the carbon dioxide bubbles in water when the pharmaceutical composition is dissolved in an intestinal tract, and lipid oil drops containing the poorly water-soluble drug form when the carbon dioxide bubbles burst at the air-liquid interface in the intestinal tract.

Abstract: A sustained-release composition is provided in the present disclosure for producing a therapeutic gas, such as hydrogen sulfide or hydrogen. The sustained-release composition includes a precursor and a carrier. The precursor is diallyl trisulfide or magnesium, and the carrier includes a poly lactic-co-glycolic acid copolymer for carrying the precursor with an efficient amount.

Abstract: The present disclosure provides a sustained-release composition including a sodium hydrosulfide and a carrier. The carrier is provided for carrying the sodium hydrosulfide with an effective amount and includes a first component and a second component. The first component includes a paraffin wax, and the second component includes a fatty alcohol, a fatty acid or a phospholipid. The present disclosure also provides a method for fabricating the sustained-release composition. The method includes providing a first solution, providing the carrier, providing a second solution, performing an oil-in-water emulsification, and cooling the emulsion. In addition, the present disclosure provides a method for treating the chronic wounds. The method includes administering an effective amount of the aforementioned sustained-release composition to a subject suffered from the chronic wounds.

Abstract: The present disclosure provides a temperature-responsive composition including a nitric oxide donor and a carrier. The nitric oxide donor is a pH-dependent material, and the carrier is provided for carrying the nitric oxide donor with an effective amount. The carrier includes a protective agent and an organic protic acid. A transition temperature of the temperature-responsive composition is larger than or equal to 28° C. and less than or equal to 37° C.

Abstract: The present invention provides a pharmaceutical composition, comprising a hydrophobic active ingredient; a surfactant having hydrophobic end and hydrophilic end; an acidic component; and an effervescent ingredient. The acidic component reacts with the effervescent ingredient in water to generate carbon dioxide. The hydrophobic ends of the surfactant surround carbon dioxide. The hydrophobic active ingredient attaches to the hydrophobic ends of the surfactant.

Abstract: The present invention provides a nano/micro bubble system for drug delivery comprising a gas core, a plurality of surfactants and an active ingredient. The surfactants surround the gas core and form a double-layer structure having an inner layer and outer layer. The active ingredient is embedded in a gap formed between the inner layer and the outer layer of the double-layer structure and comprises a nucleic acid, a peptide or a protein.

Abstract: An (acid-substituted polyaniline)-grafted hydrogel copolymer is provided. The (acid-substituted polyaniline)-grafted hydrogel copolymer has a general formula as below: wherein A is a proton acid group, m and n are same or different integers greater than 0, x is an integer equal to or greater than 0, and y is an integer equal to or greater than 1, provided that x and y are the same or different at each occurrence, and at least an x is not 0. The (acid-substituted polyaniline)-grafted hydrogel copolymer is formed by the polymerization and substitution reaction between chitosan, polyaniline, and proton acid. The (acid-substituted polyaniline)-grafted hydrogel copolymer behaves as a pH-responsive hydrogel with photo-thermal properties and can be applied to photo-thermal therapy.

Abstract: The pharmaceutical composition includes a drug layer comprising an active ingredient, a surfactant, an acidic component and an effervescent ingredient. The active ingredient comprises a nucleic acid, a peptide or a protein. The acidic component and effervescent ingredient of the drug layer are dissolved in the water to react for generating carbon dioxide and bubbles thereof. The surfactants surround the carbon dioxide gas core and form a double-layer structure having an inner layer and outer layer. The active ingredient is embedded in a gap formed between the inner layer and the outer layer of the double-layer structure.